HIGHLIGHTS
- who: Stefanie Maurer and collaborators from the Precision Immunology Institute, Department of Oncological Sciences, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA have published the Article: The Latest Breakthroughs in Immunotherapy for Acute Myeloid Leukemia, with a Special Focus on NKG2D Ligands, in the Journal: (JOURNAL) of 14/Dec/2022
- what: Given the heterogeneity of AML combined with the dynamics of clonal expansion during the course of the disease, the authors reason that a treatment regimen consisting of at least two agents is most likely to improve upon . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.